University of Pittsburgh received a five-year, $11.2 million SPORE to support the Head and Neck Cancer Specialized Program of Research Excellence at UPMC Hillman Cancer Center. This is one of two SPOREs awarded to Pitt/Hillman and one of 11 SPORES supported by NIH in 2022.
The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1.
